🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525445-73-00
Authorised Phase II

Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high

2026-525445-73-00 · tracked via the Priya Life Science EU tracker
Sponsor
UZ Brussel
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Neoplasms
Decision date
09/09/2026
Enrollment target
40
Sites
Belgium

Condition studied

TMB-high advanced neoplasms

Investigational medicinal product(s)

OPDIVO 10 mg/mL concentrate for solution for infusion.

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Overall response rate (ORR)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525445-73-00 on CTIS ↗ ← All trials in the EU